JPWO2020123980A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020123980A5 JPWO2020123980A5 JP2021534270A JP2021534270A JPWO2020123980A5 JP WO2020123980 A5 JPWO2020123980 A5 JP WO2020123980A5 JP 2021534270 A JP2021534270 A JP 2021534270A JP 2021534270 A JP2021534270 A JP 2021534270A JP WO2020123980 A5 JPWO2020123980 A5 JP WO2020123980A5
- Authority
- JP
- Japan
- Prior art keywords
- activatable
- proprotein
- polypeptide
- activatable proprotein
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 108
- 229920001184 polypeptide Polymers 0.000 claims description 103
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 103
- 230000000873 masking effect Effects 0.000 claims description 68
- 102000003812 Interleukin-15 Human genes 0.000 claims description 39
- 108090000172 Interleukin-15 Proteins 0.000 claims description 39
- 239000000427 antigen Substances 0.000 claims description 31
- 102000036639 antigens Human genes 0.000 claims description 31
- 108091007433 antigens Proteins 0.000 claims description 31
- 235000018102 proteins Nutrition 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 238000003776 cleavage reaction Methods 0.000 claims description 21
- 230000007017 scission Effects 0.000 claims description 21
- 101001003140 Homo sapiens Interleukin-15 receptor subunit alpha Proteins 0.000 claims description 18
- 102000035195 Peptidases Human genes 0.000 claims description 18
- 108091005804 Peptidases Proteins 0.000 claims description 18
- 239000004365 Protease Substances 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 15
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 8
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims description 6
- 210000000601 blood cell Anatomy 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 102000056003 human IL15 Human genes 0.000 claims description 6
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 108020001580 protein domains Proteins 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 230000005975 antitumor immune response Effects 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 3
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 claims description 3
- 102000035101 Aspartic proteases Human genes 0.000 claims description 3
- 108091005502 Aspartic proteases Proteins 0.000 claims description 3
- 102000005572 Cathepsin A Human genes 0.000 claims description 3
- 108010059081 Cathepsin A Proteins 0.000 claims description 3
- 102000004225 Cathepsin B Human genes 0.000 claims description 3
- 108090000712 Cathepsin B Proteins 0.000 claims description 3
- 102100027995 Collagenase 3 Human genes 0.000 claims description 3
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 3
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 3
- 101710088083 Glomulin Proteins 0.000 claims description 3
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims description 3
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 claims description 3
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 claims description 3
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 claims description 3
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 claims description 3
- 101001011906 Homo sapiens Matrix metalloproteinase-14 Proteins 0.000 claims description 3
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 3
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 claims description 3
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 claims description 3
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 claims description 3
- 101000577877 Homo sapiens Stromelysin-3 Proteins 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 102000001399 Kallikrein Human genes 0.000 claims description 3
- 108060005987 Kallikrein Proteins 0.000 claims description 3
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims description 3
- 102100030417 Matrilysin Human genes 0.000 claims description 3
- 108010091175 Matriptase Proteins 0.000 claims description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 3
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 claims description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 3
- 102000005741 Metalloproteases Human genes 0.000 claims description 3
- 108010006035 Metalloproteases Proteins 0.000 claims description 3
- 102100030411 Neutrophil collagenase Human genes 0.000 claims description 3
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims description 3
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 3
- 108010022999 Serine Proteases Proteins 0.000 claims description 3
- 102000012479 Serine Proteases Human genes 0.000 claims description 3
- 102100030416 Stromelysin-1 Human genes 0.000 claims description 3
- 102100028848 Stromelysin-2 Human genes 0.000 claims description 3
- 102100028847 Stromelysin-3 Human genes 0.000 claims description 3
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims description 3
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 claims description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 3
- 108010055066 asparaginylendopeptidase Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000010174 renal carcinoma Diseases 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024159011A JP2024175026A (ja) | 2018-12-14 | 2024-09-13 | Ｉｌ－１５組成物およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779793P | 2018-12-14 | 2018-12-14 | |
| US62/779,793 | 2018-12-14 | ||
| PCT/US2019/066287 WO2020123980A1 (en) | 2018-12-14 | 2019-12-13 | Il-15 compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024159011A Division JP2024175026A (ja) | 2018-12-14 | 2024-09-13 | Ｉｌ－１５組成物およびその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022513888A JP2022513888A (ja) | 2022-02-09 |
| JPWO2020123980A5 true JPWO2020123980A5 (https=) | 2022-12-06 |
| JP2022513888A5 JP2022513888A5 (https=) | 2022-12-06 |
| JP7557465B2 JP7557465B2 (ja) | 2024-09-27 |
Family
ID=71075819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534270A Active JP7557465B2 (ja) | 2018-12-14 | 2019-12-13 | Ｉｌ－１５組成物およびその使用方法 |
| JP2024159011A Pending JP2024175026A (ja) | 2018-12-14 | 2024-09-13 | Ｉｌ－１５組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024159011A Pending JP2024175026A (ja) | 2018-12-14 | 2024-09-13 | Ｉｌ－１５組成物およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230045048A1 (https=) |
| EP (1) | EP3893917A4 (https=) |
| JP (2) | JP7557465B2 (https=) |
| KR (1) | KR102911817B1 (https=) |
| CN (1) | CN114746105A (https=) |
| AU (1) | AU2019395266A1 (https=) |
| CA (1) | CA3121813A1 (https=) |
| WO (1) | WO2020123980A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| MX2022007202A (es) * | 2019-12-13 | 2022-10-07 | Cugene Inc | Fármacos bioactivables a base de citocinas y metodos de uso de los mismos. |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2021257808A2 (en) * | 2020-06-17 | 2021-12-23 | Proviva Therapeutics (Hong Kong) Limited | Antibodies to fibroblast activation protein and b7h3 |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| JP2024511387A (ja) | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| US20240228585A1 (en) * | 2021-05-03 | 2024-07-11 | President And Fellows Of Harvard College | Fc-fusion protein therapeutic for the treatment of pancreatitis |
| EP4580683A2 (en) * | 2022-08-31 | 2025-07-09 | Proviva Therapeutics (Hong Kong) Limited | Il-15 procytokine antibody fusion proteins |
| AU2023338694A1 (en) * | 2022-09-08 | 2025-04-03 | Cugene Inc. | Novel pd1-targeted il-15 immunocytokine and vitokine fusions |
| WO2024216170A2 (en) * | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2025085744A1 (en) * | 2023-10-18 | 2025-04-24 | Memorial Sloan-Kettering Cancer Center | Fusion polypeptides and uses thereof |
| WO2025180355A1 (zh) * | 2024-02-27 | 2025-09-04 | 江苏奥赛康生物医药有限公司 | Il-15前药与免疫检查点抑制剂的组合 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| ES2327830T3 (es) * | 2002-03-29 | 2009-11-04 | Schering Corporation | Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen. |
| US20110178279A1 (en) * | 2009-08-03 | 2011-07-21 | Williams John C | Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies |
| US20100189651A1 (en) * | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| JP5861223B2 (ja) * | 2009-02-23 | 2016-02-16 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | プロタンパク質およびその使用方法 |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2016004383A1 (en) * | 2014-07-03 | 2016-01-07 | City Of Hope | Tumor-selective ctla-4 antagonists |
| WO2016210447A1 (en) * | 2015-06-26 | 2016-12-29 | University Of Southern California | Masking chimeric antigen receptor t cells for tumor-specific activation |
| WO2017201352A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| CN110214147A (zh) * | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15Rα异源二聚体FC-融合蛋白 |
| KR20190102259A (ko) * | 2017-01-10 | 2019-09-03 | 인트렉손 코포레이션 | 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절 |
-
2019
- 2019-12-13 AU AU2019395266A patent/AU2019395266A1/en not_active Abandoned
- 2019-12-13 CA CA3121813A patent/CA3121813A1/en active Pending
- 2019-12-13 US US17/413,786 patent/US20230045048A1/en active Pending
- 2019-12-13 EP EP19897286.1A patent/EP3893917A4/en active Pending
- 2019-12-13 CN CN201980082406.XA patent/CN114746105A/zh active Pending
- 2019-12-13 JP JP2021534270A patent/JP7557465B2/ja active Active
- 2019-12-13 KR KR1020217018990A patent/KR102911817B1/ko active Active
- 2019-12-13 WO PCT/US2019/066287 patent/WO2020123980A1/en not_active Ceased
-
2024
- 2024-09-13 JP JP2024159011A patent/JP2024175026A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020123980A5 (https=) | ||
| US20250163153A1 (en) | Release segments and binding compositions comprising same | |
| US20250270314A1 (en) | Anti-cdh17 monoclonal and bispecific antibodies and uses thereof | |
| RU2011138951A (ru) | Пропротеины и способы их применения | |
| JP2019513014A5 (https=) | ||
| CN103687879B (zh) | 多价抗原结合fv分子 | |
| US20220098274A1 (en) | Engineered pd-1 variants | |
| WO2020061526A1 (en) | Conditionally activated target-binding molecules | |
| Rader | Chemically programmed antibodies | |
| JPWO2019213517A5 (https=) | ||
| JP2023123649A5 (https=) | ||
| JPWO2019246004A5 (https=) | ||
| CN115057936A (zh) | 异源二聚体多特异性抗体形式 | |
| RU2015101803A (ru) | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения | |
| HRP20030192A2 (en) | Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target specific prodrug | |
| JP7811217B2 (ja) | 抗ｈｅｒ２抗体－免疫アゴニストコンジュゲート及びその使用 | |
| WO2022125694A1 (en) | Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function | |
| US20220275093A1 (en) | Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and lenalidomide | |
| JP2025124718A5 (https=) | ||
| US12590159B2 (en) | Compositions targeting epidermal growth factor receptor and methods for making and using the same | |
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| KR20250133776A (ko) | 전립선-특이적 막 항원(psma)을 표적화하는 조성물 및 이의 제조 방법 및 사용 방법 | |
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| KR20250028265A (ko) | 항체 및 이의 용도 | |
| JP2023518835A (ja) | 制御性ｔ細胞の除去用の二重特異性融合タンパク質 |